FiercePharmaOriginal article
{"a":[{"_":"AbbVie lines up Qulipta expansion with phase 3 win in untapped menstrual migraine indication","$":{"href":"/pharma/abbvie-lines-qulipta-expansion-phase-3-win-untapped-menstrual-migraine-indication","hreflang":"en"}}]}
Phase 3positiveQuliptaPositive
AI Analysis
Summary
AbbVie announced positive Phase 3 results for Qulipta (atogepant) in menstrual migraine prevention, positioning the company to expand the drug's market reach into this previously untapped indication.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Phase 3 results in menstrual migraine indication
Importance:7/10
Sentiment:
0.75
migrainephase 3indication expansionatogepantwomens health
Related Companies
Read the original article
Published by FiercePharma on September 10, 2026 10:55 AM